Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.52 |
| ▸ | JUN | P05412 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559427 | 1.00 | MAPK10 (0.52) | MAPK10JUNMCHR1MAPK8MAPK9 | |
| SCHEMBL560150 | 0.86 | MAPK10 (0.56) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL560149 | 0.86 | MAPK10 (0.56) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL2257697 | 0.86 | MAPK10 (0.53) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL2257700 | 0.86 | MAPK10 (0.53) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL10165884 | 0.85 | MAPK8 (0.57) | MAPK10JUNMCHR1MAPK8MAPK9 | |
| SCHEMBL13444580 | 0.84 | MAPK10 (0.58) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL559040 | 0.83 | MAPK10 (0.61) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL559041 | 0.83 | MAPK10 (0.61) | MAPK10JUNMAPK8MAPK9TNIK | |
| SCHEMBL12378898 | 0.82 | MAPK10 (0.54) | MAPK10JUNMAPK8MAPK9TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK10 32/4885JUN 36/4885MCHR1 1552/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK10 32/4885JUN 36/4885MCHR1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.